Stalik Dzhauari

Stalik Dzhauari

Auto-generated profile, based on publicly available information

Stalik Dzhauari

Lomonosov Moscow State University

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2025 in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
Verified
Journal Article
Closed access
MKMaxim Karagyaur
Maxim Karagyaur
OAOlga Alexandrovna Averina
Olga Alexandrovna Averina
KBK. D. Bozov
K. D. Bozov
SDS. S. Dzhauari
S. S. Dzhauari
APA. V. Priymak
A. V. Priymak
Vsevolod A. TkachukVsevolod A. Tkachuk
Vsevolod A. Tkachuk
Genetic technologies open up opportunities for studying the molecular basis of a wide range of hereditary pathologies, including mental disorders. Modeling certain genomic variants in cellular and animal models allows us to establish their functional significance and potential mechanisms of involvement in the disease progression, as well as lays the material basis for the development and testing of promising drugs. Here, in this study, we created the first line of transgenic mice carrying the P654L (rs139336954) mutation in the Plxna3 nerve tissue morphogenesis protein and studied their cognitive and behavioral characteristics. The Plxna3 protein, together with the Nrp1/Nrp2 co-receptor, detects signals from the repellent molecules Sema3a and Sema3f and determines the direction of cell migration and nerve fiber growth, the processes that are crucial for the proper development of the finely tuned nervous system. According to bioinformatic analysis, this mutation alters the structure of the extracellular domain of Plxna3, which could potentially disrupt the reception of Sema3a and/or Sema3f. Studies of the behavior of mice carrying the Plxna3-P654L (rs139336954) mutation have revealed increased anxiety, a high degree of orderliness, and reduced sensitivity to external stimuli, which could potentially be interpreted as symptoms of obsessive-compulsive personality disorder. No significant macroscopic or histological differences in brain structure were detected between the control and experimental groups. In this study, we draw attention for the first time to the genomic variant rs139336954 in the Plxna3 gene as a potential cause of obsessive-compulsive personality disorder and propose a novel transgenic model organism for studying the pathogenesis of this disease.

21 March 2024 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
APAlexandra Leonidovna Primak
Alexandra Leonidovna Primak
MSM.N. Skryabina
M.N. Skryabina
SDS.S. Dzhauari
S.S. Dzhauari
Vsevolod A. TkachukVsevolod A. Tkachuk
Vsevolod A. Tkachuk
MKMaxim Karagyaur
Maxim Karagyaur
Ischemic and hemorrhagic strokes, traumatic brain injury, bacterial and viral encephalitis, toxic and metabolic encephalopathies are very different pathologies. But, they have much more in common than it might seem at first glance. In this review, the authors propose to consider these brain pathologies from the point of view of the unity of their pathogenetic mechanisms and approaches to therapy. Particular attention is paid to promising therapeutic approaches, such as therapy using cells and their secretion products: an analysis of the accumulated experimental data, the advantages and limitations of these approaches in the treatment of brain damage was carried out. The review may be of interest both to specialists in the field of neurology, neurosurgery and neurorehabilitation, and to readers who want to learn more about the progress of regenerative biomedicine in the treatment of brain pathologies.

19 January 2024 in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
Verified
Journal Article
Closed access
MKMaxim Karagyaur
Maxim Karagyaur
APA. L. Primak
A. L. Primak
KBK. D. Bozov
K. D. Bozov
DSD. A. Sheleg
D. A. Sheleg
MAMikhail Arbatsky
Mikhail Arbatsky
ENElena Neyfeld
Elena Neyfeld

31 March 2024 in Сибирский вестник психиатрии и наркологии
Verified
Journal Article
Closed access
MKMaxim Karagyaur
Maxim Karagyaur
КБК.д. Бозов
К.д. Бозов
АПА.л. Примак
А.л. Примак
ДШД.а. Шелег
Д.а. Шелег
MAMikhail Arbatsky
Mikhail Arbatsky
ENElena Neyfeld
Elena Neyfeld

25 December 2025 in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
Verified
Journal Article
Closed access
MIM. E. Illarionova
M. E. Illarionova
VIV. I. Ilyin
V. I. Ilyin
KBK. D. Bozov
K. D. Bozov
DSD. A. Sheleg
D. A. Sheleg
SDS. S. Dzhauari
S. S. Dzhauari
MKMaxim Karagyaur
Maxim Karagyaur
Recent studies indicate that the ground for certain forms of mental disorders (schizophrenia, autism, depressive disorders) may be laid by disturbances in the structure of brain tissue, caused by aberrations in the expression and functioning of brain morphogenic genes. One of the most common types of mutations found in nature is the nucleotide conversion of cytosine → deoxyuracil → thymine, methylcytosine → thymine, or guanine → adenine, caused by oxidative deamination of cytosine. That is why, in this study, we paid particular attention to this type of polymorphisms in genes of interest. We performed ARMS analysis of single nucleotide genomic variants (C/T or G/A) in brain morphogenic genes (CDH13, EPHA1, NGF, PLAU, PLXNA3) and in the glucocorticoid receptor gene NR3C1 in order to evaluate their prevalence in the genome of patients, who suffer from paranoid schizophrenia or major depressive disorder (MDD) in the Russian population. For most of the genomic variants studied, no statistically significant differences were found in their prevalence among patients with paranoid schizophrenia or MDD. However, we detected the statistically significant higher distribution of the homozygous variant rs736719-C in the CDH13 gene in patients with MDD, but not in those with paranoid schizophrenia. The functional significance of the identified genomic variant has yet to be studied using cellular and animal models. The identification of pathogenic genomic variants (confirmed by their further testing in in vivo and in vitro models) allows for a better understanding of the pathogenesis of mental disorders and opens up prospects for the development of approaches to the objective diagnosis of such diseases, their early prevention, and pathogenetic therapy.

1 June 2021 in Tissue Engineering Part C: Methods
Verified
Journal Article
Closed access
MKMaxim Karagyaur
Maxim Karagyaur
ARAlexandra Rostovtseva
Alexandra Rostovtseva
SDStalik Dzhauari
Stalik Dzhauari
EKEvgeniy Kozlov
Evgeniy Kozlov
LLLyubov Lebedeva
Lyubov Lebedeva
DSDmitry Stambolsky
Dmitry Stambolsky
Gene therapy is one of the promising approaches for regenerative medicine. Local and long-term expression of essential growth factors allows to achieve the desired therapeutic effect. However, some aspects of prolonged usage of genetic constructs encoding growth factors, such as toxicity, mutagenicity, genotoxicity, and ability to disseminate from the injection site and mediate ectopic expression of therapeutic proteins, are poorly investigated. These aspects of gene therapy drugs' usage became the subject of this study. To study plasmid biodistribution, toxicity, mutagenicity, and genotoxicity, we used previously described bicistronic genetic construct encoding human brain-derived neurotrophic factor (hBDNF) and human urokinase plasminogen activator (huPA) for nerve repair. Biodistribution studies were conducted in mice: a course of intramuscular plasmid injections was followed by the study of the content of the plasmid (real-time polymerase chain reaction) and recombinant proteins (enzyme-linked immunosorbent assay) in murine organs and tissues. The study of the plasmid chronic toxicity was carried out on rats with registration of their weight dynamics, neurological status, emotional state, and blood test parameters. The mutagenicity of the plasmid was studied in an in vivo DNA comet test in mice. Plasmid genotoxicity was investigated in the model of somatic recombination in Drosophila females. We have shown that plasmids can disseminate from the injection site, but do not mediate ectopic expression of growth factors upon repeated intramuscular injections. The studied plasmid also does not reveal toxic, mutagenic, or genotoxic effects. During the toxicological study on rats, we have shown that daily injections of this genetic construct, despite its ability to disseminate from the injection site, do not affect the physical, cognitive, and emotional state of experimental animals. We have demonstrated the safety of the bicistronic plasmid, encoding hBDNF and huPA, upon its repeated administration. The properties of genetic constructs strongly depend on their sequence and delivery approach, which requires conducting of their safety studies in each specific case. Impact statement: Gene therapy is one of the promising approaches for regenerative medicine. Local and long-term expression of essential growth factors allows to achieve the desired therapeutic effect. However, some aspects of prolonged usage of genetic constructs encoding growth factors, such as toxicity, mutagenicity, genotoxicity, and ability to disseminate from the injection site and mediate ectopic expression of therapeutic proteins, are poorly investigated. These aspects of gene therapy became the subject of this study. To our knowledge, this is a unique study that provides a thorough safety investigation of a bicistronic plasmid after its readministration.